Cergutuzumab amunaleukin (CEA-IL2v), a monomeric immunocytokine, targets carcinoembryonic antigen (CEA) and is based on an IL-2 variant. It exhibits immunostimulating and antineoplastic activities.
CAS Number:
[1509916-03-3]
* VAT and and shipping costs not included. Errors and price changes excepted
